FDA expands options for rare disease trials

Accelerate smarter with early-phase insights across regions. This edition explores how Medtech and Biopharma innovators are advancing from early feasibility to regulatory submission—while leveraging global strategies that work: Navigate the FDA’s new rare disease pathways for CGTs.

first-in-human · regulatory · FDA · MedTech · biopharma · approval

Accelerate smarter with early-phase insights across regions.

This edition explores how Medtech and Biopharma innovators are advancing from early feasibility to regulatory submission—while leveraging global strategies that work:

Navigate the FDA’s new rare disease pathways for CGTs. Discover how one device jumped from first-in-human to FDA approval. Explore Europe’s plan to fast-track oncology drug access.

Let’s get into it. 👇

← All Global Trial Accelerators editions · Contact bioaccess®